Application of breast cancer risk prediction models in clinical practice.
Breast cancer risk assessment provides an estimation of disease risk that can be used to guide management for women at all levels of risk. In addition, the likelihood that breast cancer risk is due to specific genetic susceptibility (such as BRCA1 or BRCA2 mutations) can be determined. Recent developments have reinforced the clinical importance of breast cancer risk assessment. Tamoxifen chemoprevention as well as prevention studies such as the Study of Tamoxifen and Raloxifene are available to women at increased risk of developing breast cancer. In addition, specific management strategies are now defined for BRCA1 and BRCA2 mutation carriers. Risk may be assessed as the likelihood of developing breast cancer (using risk assessment models) or as the likelihood of detecting a BRCA1 or BRCA2 mutation (using prior probability models). Each of the models has advantages and disadvantages, and all need to be interpreted in context. We review available risk assessment tools and discuss their application. As illustrated by clinical examples, optimal counseling may require the use of several models, as well as clinical judgment, to provide the most accurate and useful information to women and their families.
Domchek
Susan M
SM
University of Pennsylvania Cancer Center, 14 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA. susan.domchek@uphs.upenn.edu
Eisen
Andrea
A
Calzone
Kathleen
K
Stopfer
Jill
J
Blackwood
Anne
A
Weber
Barbara L
BL
D001943:Breast Neoplasms / Q000208:ethnology / Q000235:genetics / Q000517:prevention & control; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation / Q000235:genetics; D006801:Humans; D008954:Models, Biological; D011237:Predictive Value of Tests; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D018570:Risk Assessment; D013629:Tamoxifen / Q000627:therapeutic use*
D004965:Estrogen Antagonists; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride